Stock Analiz

Prelude Therapeutics Inc PRLD

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$3.45Market cap $275M
Open the interactive analysis →

Prelude Therapeutics Inc (PRLD) is a healthcare company listed in the US with a market value of about $275M. In the twelve months to June 30, 2026 it had revenue of $22M and net income of -$60M, a net margin of -269.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -58%.

About Prelude Therapeutics

Prelude Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 62% over three years (dilution for shareholders). It spends 777% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S12.3
P/B2.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)73.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1318.2%
ROIC (5-yr avg.)-58.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$22M$12M$7M—————
Net income-$60M-$99M-$127M-$122M-$115M-$112M-$57M-$28M
Free cash flow-$33M-$56M-$104M-$111M-$87M-$86M-$47M-$26M
EPS (diluted)$-0.73$-1.29$-1.68$-2.02$-2.44$-2.43$-4.56$-16.52
Net margin-269.7%-819.6%-1816.8%—————
ROIC—-95.6%-73.9%-41.1%-49.5%-31.2%-21.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $9.20, 167% above the current price; targets range from $6.00 to $12.00; the consensus rating is “none”; expected EPS is $-0.57 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Prelude Therapeutics pay a dividend?

Not currently.

Is Prelude Therapeutics a good stock to buy?

We do not give buy or sell advice. Prelude Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.